Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve Audited Standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aspira Pathlab & Diagnostics Ltd has informed BSE that its Board Meeting is scheduled for May 23, 2026 to consider and approve the audited Standalone Financial Results for Q4 and the year ended March 31, 2026. This is a standard regulatory intimation under SEBI Listing Regulations (Regulation 29). The company is India's first fully integrated lab and is listed on BSE with Security Code 540788. No actual financial figures or specific agenda details beyond results approval are disclosed in this notice. The notice will also be uploaded on the company's website.
This is a routine pre-results announcement. Shareholders should note that actual Q4 and full-year financial results will be disclosed after the May 23, 2026 Board meeting. No immediate impact on the stock until results are released.